Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
October 29, 2026

Formation Bio launches $600m drug development fund

US-based AI-focused pharmaceutical company Formation Bio has launched the Formation Bio Drug Development Accelerator Fund with a capital of $600m aimed at broadening the company’s clinical-stage medicines portfolio.

Continue
Formation Bio combines computational platforms with clinical trial operations to progress drug candidates. Credit: Gorodenkoff / Shutterstock.com.
October 29, 2026

Enthorin and Rumi sign agreement for FXS therapy

FXS is an inherited neurodevelopmental disorder stemming from FMR1 gene alterations. Credit: bangoland / Shutterstock.com.
October 28, 2026

Arrowhead gains UK marketing authorisation for Redemplo

The regulatory clearance was supported by results from the PALISADE study. Credit: PeopleImages / Shutterstock.com.

Contracts

January 23, 2025

Kamada to supply immune globulin products in Latin America

KAMRAB must be administered alongside a complete rabies vaccine regimen. Credit: Nappy on Unsplash.

Bavarian Nordic secures $156.8m US vaccine deal

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Deals

Deals January 20, 2025

Fermion and Simcere to partner on development of pain treatment drug

Pharmaceutical Business Review

WuXi Biologics and Sino Biopharm collaborate on monoclonal antibody discovery

Merck enhances ophthalmology portfolio with EyeBio acquisition

Biocon signs licensing and supply deal for diabetes drug in Brazil

Popular

  1. FDA grants orphan drug status to Octant’s OCT-980 for RP
  2. Regeneron agrees to $270m extension to supply Ebola medicine in US
  3. China’s NMPA accepts Innovent application for sintilimab combo
  4. Lunit and Summit to evaluate pathology platform for tumour analysis
  5. Pathos AI completes $237m Series E round to expand oncology pipeline

PRESS RELEASES

Gerresheimer Reports Slight Revenue Growth in Q1 2026 and a Strong Focus on Free Cash Flow
Gerresheimer Reports Slight Revenue Growth in Q1 2026 and a Strong Focus on Free Cash Flow
Uwe Röhrhoff Steps Down as Interim CEO of Gerresheimer AG
Uwe Röhrhoff Steps Down as Interim CEO of Gerresheimer AG
SCHOTT Pharma Expands Portfolio for Sensitive Biologics with cartriQ® BioPure
SCHOTT Pharma Expands Portfolio for Sensitive Biologics with cartriQ® BioPure
Pharmaceutical Business Review
SCHOTT Pharma and Nemera Deliver Verified Pen Injector Platform with Sterile Cartridge System
SCHOTT Pharma Invests in Sterile Cartridge Production in Hungary
SCHOTT Pharma Invests in Sterile Cartridge Production in Hungary

Suppliers

Whitepapers

Smoothly Through the Production Process: EVERIC™ Strong/Smooth Test
Smoothly Through the Production Process: EVERIC™ Strong/Smooth Test
Strengths and Weaknesses of Different Prefilled Syringes for Injections in Hospitals: A Case Study by Niklas Niederwieser and Patrick Gallagher SCHOTT AG
Strengths and Weaknesses of Different Prefilled Syringes for Injections in Hospitals: A Case Study by Niklas Niederwieser and Patrick Gallagher SCHOTT AG
Tracking the Cracking: How to Optimise Pharma Fill-and-Finish Processes by Use of Strength Testing and Fractography
Tracking the Cracking: How to Optimise Pharma Fill-and-Finish Processes by Use of Strength Testing and Fractography